Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cochlear Corp.

This article was originally published in The Gray Sheet

Executive Summary

Introduces Nucleus 24 cochlear implant with 24 channels and ESPrit ear level speech processor for use in severe-to-profoundly deaf adults and profoundly deaf children over 18 months of age. Cochlear launched the Nucleus 22 channel cochlear implant in November 1985 for use in adults and later gained approval for pediatric use. Encased in a titanium shell, Nucleus 24 "offers the maximum number of stimulating electrodes in a cochlear implant," the firm maintains in a June 26 release. The implantable portion of the device requires one-third less space than prior implants and conforms to the shape of a very young child's head," the company notes, adding that over 2,000 people currently wear the device outside the U.S., where it debuted last year...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts